Piper Sandler Upgrades Solid Biosciences to Overweight, Raises Price Target to $20
Portfolio Pulse from Benzinga Newsdesk
Piper Sandler analyst Christopher Raymond upgraded Solid Biosciences (SLDB) from Neutral to Overweight and increased the price target from $8 to $20.
March 14, 2024 | 8:57 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Solid Biosciences was upgraded by Piper Sandler from Neutral to Overweight with a price target increase from $8 to $20.
The upgrade from Neutral to Overweight by a reputable analyst, along with a significant increase in the price target, suggests a strong bullish outlook for Solid Biosciences. This is likely to positively influence investor sentiment and potentially lead to a short-term increase in SLDB's stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100